Literature DB >> 16899482

The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis.

G Davies1, A U Wells, S Doffman, S Watanabe, R Wilson.   

Abstract

Bronchiectasis patients are susceptible to infection with Pseudomonas aeruginosa. Isolation is associated with increased severity of disease, greater airflow obstruction and poorer quality of life. It is not known whether infection by P. aeruginosa is a marker of disease severity or contributes to disease progression. Consecutive non-cystic fibrosis adult bronchiectasis outpatients (n = 163) with multiple sputum cultures and follow-up pulmonary function tests were designated, according to isolation of P. aeruginosa, as "never infected" (group 1; n = 67), "intermittently isolated" (group 2; n = 82) and "chronically infected" (group 3; n = 14). Based upon change in forced expiratory volume in one second (FEV(1)) % predicted levels at >or=2 yrs after presentation, longitudinal behaviour was characterised as "improvement" (>or=10% rise), "decline" (>or=10% fall) or "stability". Baseline pulmonary-function tests and longitudinal behaviour were examined in relation to pseudomonas status. There was no difference between the groups in age, sex, smoking habit or length of follow-up. Baseline FEV(1) levels were highest in group 1 (mean+/-sd: 77.4+/-24.3) and higher in group 2 (67.3+/-25.7) than in group 3 (55.2+/-18.5). The same significant trends were seen for baseline FEV(1)/forced vital capacity ratios and diffusing capacity of the lung for carbon monoxide levels. Subsequent longitudinal behaviour was linked to baseline FEV(1) levels, which were lowest in patients with improvement and lower in association with decline than with stability. However, longitudinal behaviour did not differ between groups 1, 2 and 3, either before or after adjustment for baseline FEV(1) levels. Infection by Pseudomonas aeruginosa occurs in bronchiectasis patients with more severe impairment of pulmonary function but does not influence rate of decline in pulmonary function either before or after adjustment for baseline disease severity. Thus, Pseudomonas aeruginosa is a marker of bronchiectasis severity but is not linked to an accelerated decline in pulmonary function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16899482     DOI: 10.1183/09031936.06.00074605

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  35 in total

Review 1.  Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents.

Authors:  Jonathan Ilowite; Peter Spiegler; Heather Kessler
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 2.  Diagnosis and management of bronchiectasis.

Authors:  Maeve P Smith
Journal:  CMAJ       Date:  2017-06-19       Impact factor: 8.262

3.  Effect of airway Pseudomonas aeruginosa isolation and infection on steady-state bronchiectasis in Guangzhou, China.

Authors:  Wei-Jie Guan; Yong-Hua Gao; Gang Xu; Zhi-Ya Lin; Yan Tang; Hui-Min Li; Zhi-Min Li; Jin-Ping Zheng; Rong-Chang Chen; Nan-Shan Zhong
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

Review 4.  Inhaled Antibiotics for Gram-Negative Respiratory Infections.

Authors:  Eric Wenzler; Dustin R Fraidenburg; Tonya Scardina; Larry H Danziger
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

5.  Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry.

Authors:  Timothy R Aksamit; Anne E O'Donnell; Alan Barker; Kenneth N Olivier; Kevin L Winthrop; M Leigh Anne Daniels; Margaret Johnson; Edward Eden; David Griffith; Michael Knowles; Mark Metersky; Matthias Salathe; Byron Thomashow; Gregory Tino; Gerard Turino; Betsy Carretta; Charles L Daley
Journal:  Chest       Date:  2016-11-23       Impact factor: 9.410

6.  Lobar distribution in non-cystic fibrosis bronchiectasis predicts bacteriologic pathogen treatment.

Authors:  S Izhakian; W G Wasser; L Fuks; B Vainshelboim; B D Fox; O Fruchter; M R Kramer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-12       Impact factor: 3.267

7.  Mouse Subcutaneous BCG Vaccination and Mycobacterium tuberculosis Infection Alter the Lung and Gut Microbiota.

Authors:  Fabiola Silva; Raphaël Enaud; Elizabeth Creissen; Marcela Henao-Tamayo; Laurence Delhaes; Angelo Izzo
Journal:  Microbiol Spectr       Date:  2022-06-02

Review 8.  Airway disease in hematologic malignancies.

Authors:  Ricardo J José; Burton F Dickey; Ajay Sheshadri
Journal:  Expert Rev Respir Med       Date:  2022-02-21       Impact factor: 4.300

9.  Prognostic Factors in Adult Patients with Non-Cystic Fibrosis Bronchiectasis.

Authors:  Betina Charvet Machado; Patrícia Santos Jacques; Louise Piva Penteado; Paulo de Tarso Roth Dalcin
Journal:  Lung       Date:  2018-09-25       Impact factor: 2.584

10.  Inhaled Corticosteroid Therapy in Bronchiectasis is Associated with All-Cause Mortality: A Prospective Cohort Study.

Authors:  Kjell E J Håkansson; Katrine Fjaellegaard; Andrea Browatzki; Melda Dönmez Sin; Charlotte Suppli Ulrik
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.